- Telephone number
- 0151 556 5000
The Clatterbridge Cancer Centre provides highly specialist, tertiary, non-surgical cancer care to a population of 2.3m people in Merseyside, Cheshire and surrounding areas including the Isle of Man and South Lancashire. Our services include the National Centre for Eye Proton Therapy, the only facility of its kind in the UK providing low-energy proton beam therapy to treat rare eye cancers. We also provide inpatient care, advanced radiotherapy, chemotherapy and other systemic anti-cancer treatments (i.e. medicines) including gene therapies and immunotherapies. Another core area of our work is the support we provide for people living with and beyond cancer, including clinical therapies (e.g. physiotherapy), psychological support, benefits advice and wellbeing.
Our reputation for leading research and clinical trials grows year on year, thanks to our Academic Oncology Unit – a partnership with the University of Liverpool – and other highly research-active clinicians within the Trust.
We have hugely ambitious plans for improving cancer care even further as we expand our services with a major new 11-floor hospital in central Liverpool due to open in 2020 on the same research and healthcare campus as the University of Liverpool and Royal Liverpool University Hospital.
We’re also one of the best places to work in in the NHS, with great facilities, a supportive and welcoming environment and a culture of compassionate care where we aim to treat every patient as if they were a member of our own family. That’s why we consistently achieve some of the highest staff engagement scores in the country in the NHS National Staff Survey and why we’re officially one of the Health Service Journal’s ‘Best Places To Work In Healthcare’.
We’re here to deliver the best cancer care to the people we serve and we’re looking for applications from those who share that commitment and our values: Putting people first; Achieving excellence; Passionate about what we do; Always improving our care; and Looking to the future.